Cargando…
Alzheimer's disease therapeutic research: the path forward
The field of Alzheimer's disease therapeutic research seems poised to bring to clinic the next generation of treatments, moving beyond symptomatic benefits to modification of the underlying neurobiology of the disease. But a series of recent trials has had disappointingly negative results that...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2719107/ https://www.ncbi.nlm.nih.gov/pubmed/19674435 http://dx.doi.org/10.1186/alzrt2 |
_version_ | 1782170054750633984 |
---|---|
author | Aisen, Paul S |
author_facet | Aisen, Paul S |
author_sort | Aisen, Paul S |
collection | PubMed |
description | The field of Alzheimer's disease therapeutic research seems poised to bring to clinic the next generation of treatments, moving beyond symptomatic benefits to modification of the underlying neurobiology of the disease. But a series of recent trials has had disappointingly negative results that raise questions about our drug development strategies. Consideration of ongoing programs demonstrates difficult pitfalls. But a clear path forward is emerging. Successful strategies will utilize newly available tools to reconsider issues of diagnosis, assessment and analysis, facilitating the study of new treatments at early stages in the disease process at which they are most likely to yield major clinical benefits. |
format | Text |
id | pubmed-2719107 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-27191072009-08-03 Alzheimer's disease therapeutic research: the path forward Aisen, Paul S Alzheimers Res Ther Commentary The field of Alzheimer's disease therapeutic research seems poised to bring to clinic the next generation of treatments, moving beyond symptomatic benefits to modification of the underlying neurobiology of the disease. But a series of recent trials has had disappointingly negative results that raise questions about our drug development strategies. Consideration of ongoing programs demonstrates difficult pitfalls. But a clear path forward is emerging. Successful strategies will utilize newly available tools to reconsider issues of diagnosis, assessment and analysis, facilitating the study of new treatments at early stages in the disease process at which they are most likely to yield major clinical benefits. BioMed Central 2009-07-09 /pmc/articles/PMC2719107/ /pubmed/19674435 http://dx.doi.org/10.1186/alzrt2 Text en Copyright © 2009 BioMed Central Ltd |
spellingShingle | Commentary Aisen, Paul S Alzheimer's disease therapeutic research: the path forward |
title | Alzheimer's disease therapeutic research: the path forward |
title_full | Alzheimer's disease therapeutic research: the path forward |
title_fullStr | Alzheimer's disease therapeutic research: the path forward |
title_full_unstemmed | Alzheimer's disease therapeutic research: the path forward |
title_short | Alzheimer's disease therapeutic research: the path forward |
title_sort | alzheimer's disease therapeutic research: the path forward |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2719107/ https://www.ncbi.nlm.nih.gov/pubmed/19674435 http://dx.doi.org/10.1186/alzrt2 |
work_keys_str_mv | AT aisenpauls alzheimersdiseasetherapeuticresearchthepathforward |